ZEOX · Zeo ScientifiX, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As of April 30, 2026, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements.”View the 10-Q filed Jun 15, 2026
One customer — 14.2% of revenue (the six months ended April 30, 2026)
“During the six months ended April 30, 2026, the Company sold products and services totaling approximately $571,000 (14.2%) to a large medical practice group and distributor”
One customer — 12.7% of revenue (the six months ended April 30, 2026)
“approximately $511,000 (12.7%) to another large medical practice group and distributor”
One customer — 15.2% of revenue (the six months ended April 30, 2025)
“$341,000 (15.2%) and $228,000 (10.2%) to two individual medical practices”
One customer — 12.1% of revenue (the six months ended April 30, 2025)
“During the six months ended April 30, 2025, the Company sold products and services totaling approximately $270,000 (12.1%) to a large distributor”
One customer — 10.2% of revenue (the six months ended April 30, 2025)
“$341,000 (15.2%) and $228,000 (10.2%) to two individual medical practices”
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. John D. Kisiday, Ph.D. | Chief Science Officer | Terminated | 2026-03-27 |
| John D. Kisiday | Chief Science Officer | Appointed | 2026-01-28 |
| Ian T. Bothwell | Chief Executive Officer | Appointed | 2026-01-05 |
| Ron Borsheim | Chief Sales Officer – Aesthetics | Terminated | 2025-12-03 |
| Dr. Peter A. M. Everts, Ph.D. | Chief Scientific and Technology Officer | Resigned | 2025-07-21 |
| Ron Borsheim | Chief Sales Officer - Aesthetics | Appointed | 2025-04-02 |
| Dr. Peter A. M. Everts, Ph.D. | Chief Scientific and Technology Officer | Appointed | 2025-02-10 |
| Ian T. Bothwell | Interim Chief Executive Officer | Appointed | 2024-06-03 |
| Dr. Howard Golub | Chief Science Officer | Terminated | 2024-06-03 |
| Dr. Harry Leider | Chief Executive Officer | Terminated | 2024-06-03 |
| Dr. Maria Ines Mitrani | director | Resigned | 2023-07-11 |
| Howard L. Golub | Executive Vice President/Chief Science Officer | Appointed | 2023-06-06 |
| Harry Leider | Chief Executive Officer | Appointed | 2023-06-06 |
| Harry Leider, M.D., M.B.A. | Chief Executive Officer | Appointed | 2023-06-06 |
| Harry Leider, M.D., M.B.A. | member of the board of directors | Appointed | 2023-06-06 |
| Dr. Bhupendra Kumar Modi | Chairman of the Board and a director | Resigned | 2023-06-06 |
| Albert Mitrani | Executive Vice President of Sales | Terminated | 2023-05-15 |
| Dr. Maria Ines Mitrani | Chief Scientific Officer | Terminated | 2023-05-01 |
| John Chiste | member of the Company’s board of directors | Resigned | 2022-12-23 |
| Matthew Sinnreich | member of the Company's Board of Directors | Resigned | 2022-12-01 |
| Ian Bothwell | Interim Chief Executive Officer | Appointed | 2022-12-01 |
| Matthew Sinnreich | Acting Chief Executive Officer and President | Resigned | 2022-12-01 |
| Ryan Likes | Chief Operating Officer | Resigned | 2022-11-25 |
| Dr. Bhupendra Kumar Modi | Chairman of the Board | Appointed | 2022-09-27 |
| Matthew Sinnreich | President | Appointed | 2022-09-15 |